Apatinib Clinical Trials
20 recruitingDrug
Phase 215Phase 33Not Applicable1Phase 11
Showing 1–20 of 20 trials
Recruiting
Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Gastric Cancer
AstraZeneca572 enrolled186 locationsNCT06346392
Recruiting
Phase 2
Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer
AdebrelimabAdenocarcinoma of GE JunctionAdenocarcinoma of Stomach
Beijing Friendship Hospital49 enrolled1 locationNCT07353684
Recruiting
Phase 2
A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC
HCC
GrandPharma (China) Co., Ltd.120 enrolled3 locationsNCT07334483
Recruiting
Phase 2
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
HCC - Hepatocellular Carcinoma
Peking Union Medical College Hospital300 enrolled1 locationNCT07157969
Recruiting
Phase 2
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
Malignant Neoplasms of Digestive Organs
LaNova Medicines Zhejiang Co., Ltd.276 enrolled1 locationNCT05934331
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmBreast Tumors
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Not Applicable
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
Nanjing Tianyinshan Hospital300 enrolled1 locationNCT06893887
Recruiting
Phase 2
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
Adrenal Cortical CancerAdrenal Cortical CarcinomaAdrenal Cancer
West China Hospital28 enrolled1 locationNCT06831175
Recruiting
Phase 2
Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma
Unresectable Biliary Tract Carcinoma
Henan Cancer Hospital63 enrolled1 locationNCT06749730
Recruiting
Phase 2
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
HER2-negative Breast Cancer Brain Metastases
Beijing 302 Hospital30 enrolled1 locationNCT06418594
Recruiting
Phase 2
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Locally Advanced Thyroid Gland Carcinoma
West China Hospital75 enrolled1 locationNCT06482086
Recruiting
Phase 2
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Breast CancerBreast NeoplasmHER2-negative Breast Cancer+2 more
Fudan University620 enrolled1 locationNCT05594095
Recruiting
Phase 3
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Advanced Breast CancerHR+/HER2- Breast Cancer
Fudan University184 enrolled1 locationNCT06447623
Recruiting
Phase 1
A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies
Biliary Tract Malignancies
First Affiliated Hospital of Fujian Medical University35 enrolled1 locationNCT06181032
Recruiting
Phase 2
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
Intrahepatic Cholangiocarcinoma
Lei ZHAO20 enrolled1 locationNCT06296563
Recruiting
Phase 2
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University32 enrolled1 locationNCT06339619
Recruiting
Phase 2
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Breast Cancer Metastatic
Fudan University145 enrolled1 locationNCT05759572
Recruiting
Phase 2
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
Digestive System Cancers
Peking University Cancer Hospital & Institute39 enrolled1 locationNCT06099821
Recruiting
Phase 2
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
West China Hospital35 enrolled1 locationNCT05447702
Recruiting
Phase 3
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Nasopharyngeal Carcinoma
Sun Yat-sen University244 enrolled1 locationNCT05854849